Ming Zhao to Xenograft Model Antitumor Assays
This is a "connection" page, showing publications Ming Zhao has written about Xenograft Model Antitumor Assays.
Connection Strength
1.003
-
Antitumor Activity and Biomarker Analysis for TROP2 Antibody-Drug Conjugate Datopotamab Deruxtecan in Patient-Derived Breast Cancer Xenograft Models. Clin Cancer Res. 2025 Feb 03; 31(3):573-587.
Score: 0.238
-
Utilizing Patient-Derived Xenografts to Model Precision Oncology for Biliary Tract Cancer. Clin Cancer Res. 2025 Jan 17; 31(2):387-402.
Score: 0.237
-
The Combination of Tumor-targeting Salmonella typhimurium A1-R Plus the Autophagy-inhibitor Chloroquine Synergistically Eradicates HT1080 Fibrosarcoma Cells In Vitro and In Vivo. In Vivo. 2025; 39(1):102-109.
Score: 0.237
-
Thiostrepton suppresses colorectal cancer progression through reactive oxygen species related endoplasmic reticulum stress. Toxicol Appl Pharmacol. 2025 Feb; 495:117221.
Score: 0.236
-
Accurate and Safe Tumor Targeting of Orally-administered Salmonella typhimurium A1-R Leads to Regression of an Aggressive Fibrosarcoma in Nude Mice. In Vivo. 2024; 38(6):2601-2609.
Score: 0.055